USPTO Examiner SIFFORD JEFFREY MARK - Art Unit 1671

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
19092603COMPOSITION FOR REGULATING PRODUCTION OF INTERFERING RIBONUCLEIC ACIDMarch 2025January 2026Allow1020NoNo
19052822ADENO-ASSOCIATED VIRUS VARIANTFebruary 2025August 2025Allow611NoNo
19046064SURFACE-MODIFIED VIRAL PARTICLES AND MODULAR VIRAL PARTICLESFebruary 2025September 2025Allow720NoNo
18965925NANOBODY TARGETING INFLUENZA A VIRUS NUCLEOPROTEIN AND APPLICATION THEREOF, AND NUCLEIC ACID ENCODING NANOBODYDecember 2024August 2025Allow920YesNo
18670452CONSERVED REGION T CELL VACCINES FOR CORONAVIRUS AND METHODS OF USEMay 2024March 2025Allow1000NoNo
18639598GROUP B ADENOVIRUS-CONTAINING FORMULATIONApril 2024March 2026Allow2321YesNo
18432991COMPOSITIONS AND METHODS FOR REGULATING PRODUCTION OF AN ANTIBODY LIKE PROTEIN AND RIBONUCLEIC ACIDFebruary 2024July 2025Allow1840NoNo
18514078METHOD FOR INDUCING CELLULAR IMMUNITY TO INFECTION BY SARS-CoV-2November 2023August 2025Allow2110YesNo
18305735RESTRICTIVE EPITOPE PEPTIDE OF MAJOR HISTOCOMPATIBILITY COMPLEX B2 OF H9N2 SUBTYPE AVIAN INFLUENZA VIRUS AND APPLICATION THEREOFApril 2023December 2024Abandon2030NoNo
18186914CORONAVIRUS VACCINEMarch 2023August 2024Allow1721NoNo
18172966ADJUVANTED PROTEIN VACCINES COMPRISING MODIFIED FULL-LENGTH SPIKE PROTEIN OF SARS-COV-2 COMPOSITION AND METHODS OF USEFebruary 2023November 2025Allow3321YesNo
18165286INTERFERON-PRODUCING UNIVERSAL SARBECOVIRUS VACCINES, AND USES THEREOFFebruary 2023August 2024Allow1821NoNo
18000815MONO- AND MULTI-VALENT SARS-COV- 2 ADENOVIRAL VECTOR VACCINES AND SARS-COV-2 IMMUNE GLOBULIN AND METHODS OF USEDecember 2022February 2026Abandon3901NoNo
18071499CORONAVIRUS VACCINENovember 2022August 2024Allow2121YesNo
17916788COVID-19 VACCINE BASED ON THE MYXOMA VIRUS PLATFORMOctober 2022February 2026Abandon4001NoNo
17936273COMPOSITIONS AND METHODS FOR TREATING AND PREVENTING CORONAVIRUSESSeptember 2022January 2026Abandon3901NoNo
17906825SARS-CORONAVIRUS 2 (SARS-COV-2) SUBUNIT VACCINE CANDIDATESSeptember 2022January 2026Abandon3901NoNo
17787925HEPATITIS A VIRUS PREPARATION METHOD AND HEPATITIS A VIRUS PREPARED ACCORDING TO METHODJune 2022November 2025Allow4110YesNo
17782121VARIANT ONCOLYTIC VACCINIA VIRUS AND METHODS OF USE THEREOFJune 2022December 2025Abandon4301NoNo
17778055METHODS AND COMPOSITIONS FOR RECOMBINANT DENGUE VIRUSES OR VACCINE AND DIAGNOSTIC DEVELOPMENTMay 2022December 2025Allow4310NoNo
17745171METHOD FOR TREATING INFECTION OF SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 (SARS-COV-2)May 2022December 2024Abandon3130NoNo
17744324CELL LINE AND PRODUCING METHOD THEREOFMay 2022December 2025Abandon4301NoNo
17767132DUAL VIRUSES AND DUAL ONCOLYTIC VIRUSES AND METHODS OF TREATMENTApril 2022November 2025Abandon4301NoNo
17642717RECOMBINANT ONCOLYTIC NEWCASTLE DISEASE VIRUSES WITH INCREASED ACTIVITYMarch 2022October 2025Abandon4301NoNo
17633430CELL CULTURE MEDIUM FOR USE IN PRODUCING GENE THERAPY PRODUCTS IN BIOREACTORSFebruary 2022September 2025Abandon4401NoNo
17632874POTENCY ASSAYS FOR VIRAL VECTOR PRODUCTIONFebruary 2022September 2025Abandon4401NoNo
17632907ONCOLYTIC VACCINIA VIRUSFebruary 2022November 2025Allow4521NoNo
17630695METHOD FOR VIRAL INACTIVATIONJanuary 2022November 2025Allow4611YesNo
17579054Multipurpose Compositions for Collecting and Transporting Biological MaterialJanuary 2022December 2025Abandon4711NoNo
17596839LIPID NANOPARTICLE OR LIPOSOME DELIVERY OF HEPATITIS B VIRUS (HBV) VACCINESDecember 2021December 2025Abandon4810NoNo
17596750ARENAVIRUS VECTORS FOR HEPATITIS B VIRUS (HBV) VACCINES AND USES THEREOFDecember 2021November 2025Abandon4710NoNo
17596589SYSTEMS AND METHODS FOR GENERATING BACTERIOPHAGES ADAPTED TO INFECT A TARGET BACTERIAL STRAINDecember 2021November 2025Allow4710NoNo
17544416COMPOSITIONS AND METHODS TO TREAT VIRAL INFECTION AND CO-MORBIDITIESDecember 2021December 2024Allow3631YesNo
17500778NUCLEIC ACID CONSTRUCTS FOR VA RNA TRANSCRIPTIONOctober 2021July 2024Allow3311YesNo
17448095Methods for the Diagnosis and Detection of Viral AnalytesSeptember 2021February 2025Abandon4121NoNo
17440452MONOCLONAL ANTIBODIES FOR PREVENTION AND TREATMENT OF HERPES SIMPLEX VIRAL INFECTIONSSeptember 2021June 2025Allow4511NoNo
17432745ANTIBODIESAugust 2021October 2025Allow5021NoNo
17272443MONOCLONAL ANTIBODY 2G1 FOR BROAD-SPECTRUM NEUTRALIZATION OF EBOLA VIRUSES AND APPLICATION THEREOFAugust 2021July 2025Allow5220NoNo
17400136METHOD, SYSTEM AND APPARATUS FOR DETECTIONAugust 2021July 2025Abandon4701NoNo
17400086METHODS AND KITS FOR DETECTING SARS-CORONAVIRUS-2 ANTIGENAugust 2021March 2026Abandon5521NoNo
17429454Proliferation MethodAugust 2021February 2025Allow4310NoNo
17427546METHODS FOR DETECTION AND CHARACTERIZATION OF ANTI-VIRAL VECTOR ANTIBODIESJuly 2021February 2025Abandon4201NoNo
17389473Lateral Flow Device for Detecting SARS-CoV-2 Antibodies in Human and Animal SamplesJuly 2021August 2024Allow3711YesNo
17389645Quantum Dot Conjugated Virus Spike Protein for Cell-Based Bio-Sensing Systems and Drug ScreeningJuly 2021October 2025Allow5121NoNo
17425535Methods for providing purified viral particles of Semliki Forest Virus (SFV), preparations obtainable thereby, and uses thereofJuly 2021November 2025Abandon5211NoNo
17421999METHODS FOR SCREENING INHIBITORS AGAINST CHIKUNGUNYA VIRUS AND FOR DETERMINING WHETHER SUBJECTS ARE PREDISPOSED TO INFECTION BY SAID VIRUSJuly 2021March 2025Abandon4411NoNo
17420444COMPOSITIONS AND METHODS FOR URINE SAMPLE STORAGE AND DNA EXTRACTIONJuly 2021December 2024Abandon4101NoNo
17361486VIRUS LIKE NANOPARTICLE COMPOSITIONS AND METHODS THEREOFJune 2021July 2024Allow3711NoNo
17418357GP38-TARGETING MONOCLONAL ANTIBODIES PROTECT ADULT MICE AGAINST LETHAL CRIMEAN-CONGO HEMORRHAGIC FEVER VIRUS INFECTIONJune 2021October 2025Abandon5221NoNo
17418197NOROVIRUS VACCINESJune 2021December 2024Abandon4101NoNo
17417455RECOMBINANT VIRUSES AND THE USES THEREOFJune 2021August 2025Allow5021YesNo
17414267RECOMBINANT AVIAN HERPES VIRUSES CONTAINING MULTIPLE FOREIGN GENESJune 2021October 2025Abandon5221YesNo
17295798ANTIBODY THERAPIES FOR HUMAN IMMUNODEFICIENCY VIRUS (HIV)May 2021June 2025Allow4921NoNo
17295761CELLS FOR THE PRODUCTION OF VIRUSES AND METHODS OF USING THE SAMEMay 2021June 2025Allow4821NoNo
17295835VSV CHIMERIC VECTORSMay 2021September 2025Allow5231NoNo
17315055METHOD FOR DIAGNOSING SARS-COV-2 INFECTIONMay 2021March 2025Abandon4641YesNo
17245355METHODS OF GENERATING VACCINES AGAINST NOVEL CORONAVIRUS, NAMED SARS-COV-2 COMPRISING VARIABLE EPITOPE LIBRARIES (VELs) AS IMMUNOGENSApril 2021February 2025Abandon4531NoNo
17246360METHODS AND KITS FOR VIRUS DETECTIONApril 2021January 2025Abandon4521NoNo
17244642DYSREGULATION OF TRAUMA REGULATION PATHWAY TREATMENT AND MONITORING TECHNIQUESApril 2021July 2024Allow3931YesNo
17288227ONCOLYTIC VIRUS FOR CANCER THERAPYApril 2021January 2025Allow4511YesNo
17222463Bacteriophage-Based Antibodies and BindersApril 2021March 2025Abandon4831YesYes
17200297Compositions and Methods for Inducing an Immune ResponseMarch 2021December 2024Abandon4521YesNo
17271843HUMAN MONOCLONAL ANTIBODIES THAT NEUTRALIZE PANDEMIC GII.4 NOROVIRUSESFebruary 2021August 2024Allow4211YesNo
17180351Composition and Methods for Treating Infectious Agents Using Pathogen-specific AntibodiesFebruary 2021October 2023Abandon3141NoNo
17055318VIRAL VECTORS EXHIBITING IMPROVED GENE DELIVERY PROPERTIESNovember 2020August 2024Allow4511NoNo
17044645NEOADJUVANT CANCER TREATMENTOctober 2020April 2025Abandon5431NoNo
16980821INCREASING TISSUE SPECIFIC GENE DELIVERY BY CAPSID MODIFICATIONSeptember 2020April 2025Allow5531YesNo
16980282ONCOLYTIC VACCINIA VIRUS EXPRESSING IMMUNE CHECKPOINT BLOCKADE FOR CANCER IMMUNOTHERAPYSeptember 2020January 2025Abandon5211NoNo
16978288INSECT CELL MANUFACTURED PARTIAL SELF-COMPLEMENTARY AAV GENOMESSeptember 2020July 2025Abandon5821NoNo
16970163PROBE FOR UNIVERSAL DETECTION OF CIRCULATING TUMOR CELLSAugust 2020August 2024Allow4821YesNo
16969143VIRUS-LIKE NANOCAPSID FOR ORAL DELIVERY OF INSULINAugust 2020October 2025Abandon6021YesNo
16484487REBOOTING OF SYNTHETIC BACTERIOPHAGE GENOME IN L-FORM BACTERIAAugust 2019January 2025Abandon6021NoNo

Appeals Overview

This analysis examines appeal outcomes and the strategic value of filing appeals for examiner SIFFORD, JEFFREY MARK.

Strategic Value of Filing an Appeal

Total Appeal Filings
1
Allowed After Appeal Filing
0
(0.0%)
Not Allowed After Appeal Filing
1
(100.0%)
Filing Benefit Percentile
1.0%
Lower than average

Understanding Appeal Filing Strategy

Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.

In this dataset, 0.0% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.

Strategic Recommendations

Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.

Examiner SIFFORD, JEFFREY MARK - Prosecution Strategy Guide

Executive Summary

Examiner SIFFORD, JEFFREY MARK works in Art Unit 1671 and has examined 43 patent applications in our dataset. With an allowance rate of 46.5%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 47 months.

Allowance Patterns

Examiner SIFFORD, JEFFREY MARK's allowance rate of 46.5% places them in the 10% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.

Office Action Patterns

On average, applications examined by SIFFORD, JEFFREY MARK receive 1.74 office actions before reaching final disposition. This places the examiner in the 38% percentile for office actions issued. This examiner issues fewer office actions than average, which may indicate efficient prosecution or a more lenient examination style.

Prosecution Timeline

The median time to disposition (half-life) for applications examined by SIFFORD, JEFFREY MARK is 47 months. This places the examiner in the 9% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.

Interview Effectiveness

Conducting an examiner interview provides a +26.4% benefit to allowance rate for applications examined by SIFFORD, JEFFREY MARK. This interview benefit is in the 73% percentile among all examiners. Recommendation: Interviews provide an above-average benefit with this examiner and are worth considering.

Request for Continued Examination (RCE) Effectiveness

When applicants file an RCE with this examiner, 34.8% of applications are subsequently allowed. This success rate is in the 77% percentile among all examiners. Strategic Insight: RCEs are highly effective with this examiner compared to others. If you receive a final rejection, filing an RCE with substantive amendments or arguments has a strong likelihood of success.

After-Final Amendment Practice

This examiner enters after-final amendments leading to allowance in 57.1% of cases where such amendments are filed. This entry rate is in the 83% percentile among all examiners. Strategic Recommendation: This examiner is highly receptive to after-final amendments compared to other examiners. Per MPEP § 714.12, after-final amendments may be entered "under justifiable circumstances." Consider filing after-final amendments with a clear showing of allowability rather than immediately filing an RCE, as this examiner frequently enters such amendments.

Pre-Appeal Conference Effectiveness

When applicants request a pre-appeal conference (PAC) with this examiner, 200.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 93% percentile among all examiners. Strategic Recommendation: Pre-appeal conferences are highly effective with this examiner compared to others. Before filing a full appeal brief, strongly consider requesting a PAC. The PAC provides an opportunity for the examiner and supervisory personnel to reconsider the rejection before the case proceeds to the PTAB.

Appeal Withdrawal and Reconsideration

This examiner withdraws rejections or reopens prosecution in 100.0% of appeals filed. This is in the 87% percentile among all examiners. Of these withdrawals, 100.0% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner frequently reconsiders rejections during the appeal process compared to other examiners. Per MPEP § 1207.01, all appeals must go through a mandatory appeal conference. Filing a Notice of Appeal may prompt favorable reconsideration even before you file an Appeal Brief.

Petition Practice

When applicants file petitions regarding this examiner's actions, 80.0% are granted (fully or in part). This grant rate is in the 83% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.

Examiner Cooperation and Flexibility

Examiner's Amendments: This examiner makes examiner's amendments in 0.0% of allowed cases (in the 3% percentile). This examiner rarely makes examiner's amendments compared to other examiners. You should expect to make all necessary claim amendments yourself through formal amendment practice.

Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 3% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.

Prosecution Strategy Recommendations

Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:

  • Prepare for rigorous examination: With a below-average allowance rate, ensure your application has strong written description and enablement support. Consider filing a continuation if you need to add new matter.
  • Consider after-final amendments: This examiner frequently enters after-final amendments. If you can clearly overcome rejections with claim amendments, file an after-final amendment before resorting to an RCE.
  • RCEs are effective: This examiner has a high allowance rate after RCE compared to others. If you receive a final rejection and have substantive amendments or arguments, an RCE is likely to be successful.
  • Request pre-appeal conferences: PACs are highly effective with this examiner. Before filing a full appeal brief, request a PAC to potentially resolve issues without full PTAB review.
  • Appeal filing as negotiation tool: This examiner frequently reconsiders rejections during the appeal process. Filing a Notice of Appeal may prompt favorable reconsideration during the mandatory appeal conference.
  • Plan for extended prosecution: Applications take longer than average with this examiner. Factor this into your continuation strategy and client communications.

Relevant MPEP Sections for Prosecution Strategy

  • MPEP § 713.10: Examiner interviews - available before Notice of Allowance or transfer to PTAB
  • MPEP § 714.12: After-final amendments - may be entered "under justifiable circumstances"
  • MPEP § 1002.02(c): Petitionable matters to Technology Center Director
  • MPEP § 1004: Actions requiring primary examiner signature (allowances, final rejections, examiner's answers)
  • MPEP § 1207.01: Appeal conferences - mandatory for all appeals
  • MPEP § 1214.07: Reopening prosecution after appeal

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.